Cargando…

Evaluation of CIN2/3 Lesion Regression in GynTect(®) DNA Methylation-Marker-Negative Patients in a Longitudinal Study

SIMPLE SUMMARY: Precancerous cervical lesions, especially among young women, are frequently cleared by the immune system. Consequently, immediate surgical treatment is not mandatory and patients are monitored closely for up to 24 months. To avoid anxiety and to allow for a more individualized treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoyer, Heike, Stolte, Claudia, Böhmer, Gerd, Hampl, Monika, Hagemann, Ingke, Maier, Elisabeth, Denecke, Agnieszka, Hirchenhain, Christine, Patzke, Jan, Jentschke, Matthias, Gerick, Axel, Heller, Tabitha, Hippe, Juliane, Wunsch, Kristina, Schmitz, Martina, Dürst, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417134/
https://www.ncbi.nlm.nih.gov/pubmed/37568767
http://dx.doi.org/10.3390/cancers15153951
_version_ 1785087950606827520
author Hoyer, Heike
Stolte, Claudia
Böhmer, Gerd
Hampl, Monika
Hagemann, Ingke
Maier, Elisabeth
Denecke, Agnieszka
Hirchenhain, Christine
Patzke, Jan
Jentschke, Matthias
Gerick, Axel
Heller, Tabitha
Hippe, Juliane
Wunsch, Kristina
Schmitz, Martina
Dürst, Matthias
author_facet Hoyer, Heike
Stolte, Claudia
Böhmer, Gerd
Hampl, Monika
Hagemann, Ingke
Maier, Elisabeth
Denecke, Agnieszka
Hirchenhain, Christine
Patzke, Jan
Jentschke, Matthias
Gerick, Axel
Heller, Tabitha
Hippe, Juliane
Wunsch, Kristina
Schmitz, Martina
Dürst, Matthias
author_sort Hoyer, Heike
collection PubMed
description SIMPLE SUMMARY: Precancerous cervical lesions, especially among young women, are frequently cleared by the immune system. Consequently, immediate surgical treatment is not mandatory and patients are monitored closely for up to 24 months. To avoid anxiety and to allow for a more individualized treatment, molecular markers that could predict the outcome of the lesion would be desirable. Women with a high risk of progression could be identified earlier. In this study, we could show that the majority of lesions that were negative for the cancer-associated methylation markers comprising the test GynTect(®) have regressed over time. ABSTRACT: Cervical intraepithelial neoplasia (CIN) grade 2/3 has a high spontaneous regression rate, especially among women ≤29 years of age. To reduce overtreatment, reliable prognostic biomarkers would be helpful. The main aim of this study was to analyze the negative predictive value of the methylation marker panel GynTect(®) for lesion regression. In this prospective, multicenter, longitudinal observational proof-of-concept study, women aged ≤29 years with histologically confirmed CIN2 (n = 24) or CIN3 (n = 36) were closely monitored without treatment for up to 24 or 12 months, respectively. The outcome was either regression, persistence, or progression of the lesion. For each patient, a single baseline sample (V0) for cytology, hrHPV detection and methylation analysis was taken. In a primary analysis, the negative predictive value (NPV) of a GynTect(®)-negative test result at V0 for regression was determined. We tested the null hypothesis NPV ≤ 70% against the alternative hypothesis NPV ≥ 90%. Twelve of the eighteen GynTect(®)-negative CIN2 patients showed regression (NPV = 67%, 90% CI 44–85%, p = 0.53). Of the 27 GynTect(®)-negative CIN3 lesions, 15 regressed (NPV = 56%, 90% CI 38–72%, p = 0.92). Although the majority of GynTect(®)-negative lesions regressed, the postulated NPV of ≥90% was not observed. Thus, the clinical relevance for an implementation of the GynTect(®) assay for patients undergoing watchful waiting remains questionable. Further studies with longer observation periods should be undertaken.
format Online
Article
Text
id pubmed-10417134
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104171342023-08-12 Evaluation of CIN2/3 Lesion Regression in GynTect(®) DNA Methylation-Marker-Negative Patients in a Longitudinal Study Hoyer, Heike Stolte, Claudia Böhmer, Gerd Hampl, Monika Hagemann, Ingke Maier, Elisabeth Denecke, Agnieszka Hirchenhain, Christine Patzke, Jan Jentschke, Matthias Gerick, Axel Heller, Tabitha Hippe, Juliane Wunsch, Kristina Schmitz, Martina Dürst, Matthias Cancers (Basel) Article SIMPLE SUMMARY: Precancerous cervical lesions, especially among young women, are frequently cleared by the immune system. Consequently, immediate surgical treatment is not mandatory and patients are monitored closely for up to 24 months. To avoid anxiety and to allow for a more individualized treatment, molecular markers that could predict the outcome of the lesion would be desirable. Women with a high risk of progression could be identified earlier. In this study, we could show that the majority of lesions that were negative for the cancer-associated methylation markers comprising the test GynTect(®) have regressed over time. ABSTRACT: Cervical intraepithelial neoplasia (CIN) grade 2/3 has a high spontaneous regression rate, especially among women ≤29 years of age. To reduce overtreatment, reliable prognostic biomarkers would be helpful. The main aim of this study was to analyze the negative predictive value of the methylation marker panel GynTect(®) for lesion regression. In this prospective, multicenter, longitudinal observational proof-of-concept study, women aged ≤29 years with histologically confirmed CIN2 (n = 24) or CIN3 (n = 36) were closely monitored without treatment for up to 24 or 12 months, respectively. The outcome was either regression, persistence, or progression of the lesion. For each patient, a single baseline sample (V0) for cytology, hrHPV detection and methylation analysis was taken. In a primary analysis, the negative predictive value (NPV) of a GynTect(®)-negative test result at V0 for regression was determined. We tested the null hypothesis NPV ≤ 70% against the alternative hypothesis NPV ≥ 90%. Twelve of the eighteen GynTect(®)-negative CIN2 patients showed regression (NPV = 67%, 90% CI 44–85%, p = 0.53). Of the 27 GynTect(®)-negative CIN3 lesions, 15 regressed (NPV = 56%, 90% CI 38–72%, p = 0.92). Although the majority of GynTect(®)-negative lesions regressed, the postulated NPV of ≥90% was not observed. Thus, the clinical relevance for an implementation of the GynTect(®) assay for patients undergoing watchful waiting remains questionable. Further studies with longer observation periods should be undertaken. MDPI 2023-08-03 /pmc/articles/PMC10417134/ /pubmed/37568767 http://dx.doi.org/10.3390/cancers15153951 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hoyer, Heike
Stolte, Claudia
Böhmer, Gerd
Hampl, Monika
Hagemann, Ingke
Maier, Elisabeth
Denecke, Agnieszka
Hirchenhain, Christine
Patzke, Jan
Jentschke, Matthias
Gerick, Axel
Heller, Tabitha
Hippe, Juliane
Wunsch, Kristina
Schmitz, Martina
Dürst, Matthias
Evaluation of CIN2/3 Lesion Regression in GynTect(®) DNA Methylation-Marker-Negative Patients in a Longitudinal Study
title Evaluation of CIN2/3 Lesion Regression in GynTect(®) DNA Methylation-Marker-Negative Patients in a Longitudinal Study
title_full Evaluation of CIN2/3 Lesion Regression in GynTect(®) DNA Methylation-Marker-Negative Patients in a Longitudinal Study
title_fullStr Evaluation of CIN2/3 Lesion Regression in GynTect(®) DNA Methylation-Marker-Negative Patients in a Longitudinal Study
title_full_unstemmed Evaluation of CIN2/3 Lesion Regression in GynTect(®) DNA Methylation-Marker-Negative Patients in a Longitudinal Study
title_short Evaluation of CIN2/3 Lesion Regression in GynTect(®) DNA Methylation-Marker-Negative Patients in a Longitudinal Study
title_sort evaluation of cin2/3 lesion regression in gyntect(®) dna methylation-marker-negative patients in a longitudinal study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417134/
https://www.ncbi.nlm.nih.gov/pubmed/37568767
http://dx.doi.org/10.3390/cancers15153951
work_keys_str_mv AT hoyerheike evaluationofcin23lesionregressioningyntectdnamethylationmarkernegativepatientsinalongitudinalstudy
AT stolteclaudia evaluationofcin23lesionregressioningyntectdnamethylationmarkernegativepatientsinalongitudinalstudy
AT bohmergerd evaluationofcin23lesionregressioningyntectdnamethylationmarkernegativepatientsinalongitudinalstudy
AT hamplmonika evaluationofcin23lesionregressioningyntectdnamethylationmarkernegativepatientsinalongitudinalstudy
AT hagemanningke evaluationofcin23lesionregressioningyntectdnamethylationmarkernegativepatientsinalongitudinalstudy
AT maierelisabeth evaluationofcin23lesionregressioningyntectdnamethylationmarkernegativepatientsinalongitudinalstudy
AT deneckeagnieszka evaluationofcin23lesionregressioningyntectdnamethylationmarkernegativepatientsinalongitudinalstudy
AT hirchenhainchristine evaluationofcin23lesionregressioningyntectdnamethylationmarkernegativepatientsinalongitudinalstudy
AT patzkejan evaluationofcin23lesionregressioningyntectdnamethylationmarkernegativepatientsinalongitudinalstudy
AT jentschkematthias evaluationofcin23lesionregressioningyntectdnamethylationmarkernegativepatientsinalongitudinalstudy
AT gerickaxel evaluationofcin23lesionregressioningyntectdnamethylationmarkernegativepatientsinalongitudinalstudy
AT hellertabitha evaluationofcin23lesionregressioningyntectdnamethylationmarkernegativepatientsinalongitudinalstudy
AT hippejuliane evaluationofcin23lesionregressioningyntectdnamethylationmarkernegativepatientsinalongitudinalstudy
AT wunschkristina evaluationofcin23lesionregressioningyntectdnamethylationmarkernegativepatientsinalongitudinalstudy
AT schmitzmartina evaluationofcin23lesionregressioningyntectdnamethylationmarkernegativepatientsinalongitudinalstudy
AT durstmatthias evaluationofcin23lesionregressioningyntectdnamethylationmarkernegativepatientsinalongitudinalstudy